Ortivus AB (publ) quarterly report for the period July – September 2020

Ortivus' customer deliveries continue at a high pace despite Covid-19

Highlights July – Sep 2020

  • Hardware delivery of 12.0 MSEK to South Central Ambulance Service performed
  • Important milestone passed for the delivery project in Singapore
  • Ortivus and SCHILLER AG signed a distribution agreement for the Nordic market

Highlights post-period end

  • Ortivus begins the process of moving operations, such as production and reparations of MobiMed monitoring equipment, in-house.

July – Sep 2020

  • Net sales amounted to 25.4 (10.4) MSEK, which is an increase in sales of 144%
  • Operating profit cleared for comparative distortion items amounted to 1.2 (-0.8) MSEK. Operating profit, including comparative distortion items, amounted to 1.2 (-3.3) MSEK
  • EBITDA cleared for comparative distortion items, amounted to 2.0 (1.0) MSEK. EBITDA including comparative distortion items, amounted to 2.0 (-1.6) MSEK
  • Profit after tax was 1.2 (-3.3) MSEK
  • Earnings per share after tax and before and after dilution amounted to 0.03 (-0.09) SEK

Jan – Sep 2020

  • Net sales amounted to 85.2 (33.7) MSEK, which is an increase in sales of 154%
  • Operating profit cleared for comparative distortion items, amounted to 9.2 (-8.5) MSEK. Operating profit including comparative distortion items, amounted to 9.2 (-13.7) MSEK
  • EBITDA cleared for comparative distortion items, amounted to 11.4 (-3.5) MSEK. EBITDA including comparative distortion items, amounted to 11.4 (-8.7) MSEK
  • Profit after tax was 9.1 (-14.2) MSEK
  • Earnings per share after tax and before and after dilution, amounted to 0.21 (-0.42) SEK
Amount in KSEK Jul-Sep 2020 Jul-Sep 2019 Jan-Sep 2020 Jan-Sep 2019 Jan-Dec 2019
Net sales 25 351 10 407 85 719 33 747 50 848
Gross margin, % 31% 28% 33% 37% 41%
Operating profit,
excl. comparative distortion items		 1 229 -757 9 225 -8 466 -10 197
Operating margin, %
excl. comparative distortion items		 5% -7% 11% -25% -20%
EBITDA,
excl. comparative distortion items		 2 024 1 018 11 437 -3 471 -3 271

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus was founded in 1985, based on clinical experience in cardiology, and has its headquarters in Danderyd, outside Stockholm. The company has had a presence in the UK through its own subsidiary since 1998. Through its proprietary, module-based MobiMed technology platform, Ortivus offers its customers real-time monitoring of patients in prehospital care and MobiMed ePR – a decision support system that can be integrated in real time with patient management systems in the healthcare setting and with external patient systems. Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-11-10 08:30 CET.

Attachments

Quarterly Report Jul Sep 2020

This entry was posted in . Bookmark the permalink.